Predictors of Response to Pharmacotherapy in Social Anxiety Disorder: An Analysis of 3 Placebo-Controlled Paroxetine Trials
J Clin Psychiatry 2002;63:152-155
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: There is increasing evidence that
patients with social anxiety disorder (social phobia) respond to
treatment with selective serotonin reuptake inhibitors (SSRIs).
Response rates to SSRIs in social anxiety disorder have ranged
from at least 50% in controlled trials to up to 80% in open
trials. To date, however, there has been little information
available about predictors of response to treatment in this
Method: Data from 3 placebo-controlled
multicenter trials of paroxetine in DSM-IV social anxiety
disorder (N = 829) were analyzed using logistic regression to
determine predictors of response. Demographic (age, sex),
physiologic (baseline heart rate, baseline mean arterial
pressure), clinical (baseline social anxiety symptom severity,
baseline disability, duration of illness), and trial variables
(paroxetine dose, treatment duration) were included.
Results: Only duration of treatment was a
statistically significant predictor of treatment response.
Further analysis demonstrated that, in paroxetine-treated
patients in particular, many nonresponders at week 8 (46/166;
27.7%) were responders at week 12.
Conclusion: These data demonstrate that
paroxetine is a reasonable choice of treatment in a broad
spectrum of patients with social anxiety disorder. An optimal
trial of medication should continue beyond 8 weeks.